TICKERNERD
Menu
ORICORICHealthcare · Biotechnology

ORIC Stock Forecast: Oric Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 22 Oct 2026
$14
−1.59% on the day

The 16 Wall Street analysts covering Oric Pharmaceuticals, Inc. hold a median 12-month price target of $24 — +72.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 53 of 100 as at 22 Oct 2026 — in the upper half.

Market cap
$1.4B
Ticker Nerd rank
53/ 100
Median analyst target
$24
Analysts covering
16
Revenue$0.0
Operating income−$45.3M
Net income−$41.5M
Free cash flow−$32.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+6.7%
1M
+1.0%
YTD
+66.6%
1Y
+12.8%
From 52W high
−7.0%
From 52W low
+82.3%
$7
$15
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ORIC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Oric Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Oct 2026
53/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
80
Momentum
77
Quality
66
Volatility
64
Growth
59
Accruals
42
Size
40
Revisions
36
Issuance
29

Value (80): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (29): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ORIC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ORIC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25$30Jan 26Apr 26Jul 26Oct 26ORICHigh $27Median $24Low $14

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says16 analysts
15 Buy1 Hold0 Sell
Low $14Median $24High $27

The green dot is the last close — the median target sits +72.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 Oct 2026JP MorganMaintainsOverweight$23 → $26
5 Oct 2026Leerink PartnersInitiatesOutperform$26
5 Oct 2026Leerink PartnersInitiatesOutperform—
23 Sept 2026BTIGInitiatesBuy—
23 Sept 2026BTIGInitiatesBuy$26
10 Aug 2026HC Wainwright & Co.MaintainsBuy$25 → $27
10 Aug 2026HC Wainwright & Co.MaintainsBuy—
8 June 2026HC Wainwright & Co.ReiteratesBuy—
8 June 2026HC Wainwright & Co.ReiteratesBuy$25
15 May 2026Goldman SachsUpgradeBuy—
5 May 2026CitigroupMaintainsBuy—
2 Apr 2026HC Wainwright & Co.ReiteratesBuy—
1 Apr 2026WedbushMaintainsOutperform—
13 Mar 2026HC Wainwright & Co.ReiteratesBuy—
24 Feb 2026CitigroupMaintainsBuy—
24 Feb 2026HC Wainwright & Co.MaintainsBuy—
24 Feb 2026WedbushReiteratesOutperform—
13 Jan 2026WedbushReiteratesOutperform—
7 Jan 2026Piper SandlerInitiatesOverweight—
8 Dec 2025WedbushReiteratesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

ORIC appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.
  • The AI build-out, every Wednesday: how AI stocks did, part by part.

Free. Unsubscribe any time.

Performance

ORIC vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 22 Oct 2026, Oric Pharmaceuticals, Inc. returned +12.8% against +15.6% for the S&P 500, dividends included.

ORIC vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110120Jan 26Apr 26Jul 26Oct 26ORICS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ORIC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Oric Pharmaceuticals, Inc. (ORIC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−9.4×

Cheaper than 93% of US stocks

Price / sales
—
Price / book
3.8×

Cheaper than 25% of US stocks

EV / EBITDA
−7.6×

Cheaper than 84% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−39.8%

Higher than 24% of US stocks

Return on assets
−26.0%

Higher than 16% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Oric Pharmaceuticals, Inc. (ORIC) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Oric Pharmaceuticals, Inc. has a market value of $1.4B and an enterprise value of $1.2B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$140.4M.

  • Diluted earnings per share, trailing twelve months: $−1.35.

  • Free cash flow in the twelve months to 30 June 2026: −$112.3M.

  • Shares outstanding: 103.6M.

  • Trailing P/E: −9.4×; forward P/E: −8.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Oric Pharmaceuticals, Inc. employs 111 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Oct 2026

Data provided by Twelve Data

Peers

ORIC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ORICOric Pharmaceuticals, Inc.$1.4B53
ANABAnaptysBio, Inc.$1.4B95
INBXInhibrx Biosciences, Inc.$1.4B25
TYRATyra Biosciences, Inc.$1.4B37
OCULOcular Therapeutix, Inc.$1.5B32
TRAXFirst Tracks Biotherapeutics, Inc.$1.5B1
DMRADamora Therapeutics, Inc.$1.3B37

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Oric Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ORIC news & analysis

ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 Trial

GlobeNewsWire · 23 Oct 2026positive

ORIC reported enozertinib data in first-line NSCLC patients with EGFR atypical mutations at the ESMO Congress 2026, including confirmed systemic ORR of 84% and intracranial ORR of 70%, with multiple intracranial complete responses. The company plans to advance enozertinib into a global Phase 3 trial.

Why it matters — The reported response rates and planned Phase 3 trial are relevant to ORIC watchers tracking the drug’s clinical progress.

ORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress 2026

GlobeNewsWire · 23 Oct 2026positive

ORIC Pharmaceuticals presented preclinical and translational data at the ESMO Congress 2026 on rinzimetostat’s potential to enhance sensitivity to androgen receptor inhibition in prostate cancer. The excerpt says rinzimetostat maintained effectiveness against resistance mutations that emerge with EZH2 inhibitors such as mevrometostat.

Why it matters — The data give ORIC watchers information about the proposed rationale for targeting PRC2 through EED with rinzimetostat.

ORIC® Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026

GlobeNewsWire · 19 Oct 2026neutral

ORIC Pharmaceuticals will host a conference call and webcast on October 23, 2026, at 8:00 a.m. ET to review enozertinib data being presented at the ESMO Congress. Dr. Joshua Sabari will discuss the clinical data and enozertinib’s potential for first-line NSCLC patients with EGFR atypical mutations.

Why it matters — ORIC watchers may be interested in the upcoming discussion of clinical data for enozertinib in this patient group.

ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development

GlobeNewsWire · 5 Oct 2026positive

ORIC Pharmaceuticals announced an agreement with Cancer Research UK to advance ORIC-259, a potential first-in-class small molecule mRNA degrader targeting CIP2A, into clinical development. Cancer Research UK will fully fund, sponsor, design, and execute CTA-enabling studies and Phase 1/2 clinical development, while ORIC retains an exclusive option to reacquire rights to the program following Phase 1/2 data.

Why it matters — ORIC watchers would care because this partnership moves a potential first-in-class CIP2A-targeted therapy into the clinic with external funding, while ORIC retains the option to regain full rights after early-stage data.

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 2 Oct 2026neutral

ORIC Pharmaceuticals announced that on October 1, 2026, it granted 161,550 non-qualified stock options and 26,850 restricted stock units to six new non-executive employees who joined the company in September 2026. The inducement grants were made under Nasdaq Listing Rule 5635(c)(4).

Why it matters — The inducement grants signal ORIC's continued hiring of new employees to support its clinical-stage oncology pipeline, which investors tracking the company's growth and talent additions would note.

FAQ

Frequently asked questions about ORIC stock

What is the ORIC stock price forecast for 2026-2027?

The 16 Wall Street analysts covering Oric Pharmaceuticals, Inc. have a median 12-month price target of $24, with estimates ranging from $14 to $27. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ORIC stock a buy right now?

Of the 16 analysts covering Oric Pharmaceuticals, Inc., 15 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Oric Pharmaceuticals, Inc. 53 out of 100 across roughly 4,600 US stocks as at 22 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ORIC?

As at 22 Oct 2026, Oric Pharmaceuticals, Inc. ranks 53 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (80 of 100).

Will ORIC stock go up?

No one can know that. What the data says: the median 12-month target from 16 analysts implies +72.4% from the last close, and Ticker Nerd's factor model ranks Oric Pharmaceuticals, Inc. 53 out of 100 as at 22 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ORIC stock forecast for 2030?

No analyst covering Oric Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ORIC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $27 over the next 12 months.

How has ORIC stock performed over the past year?

Oric Pharmaceuticals, Inc. returned +12.8% over the 12 months to 22 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Oric Pharmaceuticals, Inc. do?

Oric Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapies that address resistance to treatment.

What is the latest news on ORIC?

The most recent item we track (GlobeNewsWire, 23 Oct 2026): "ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 Trial". ORIC reported enozertinib data in first-line NSCLC patients with EGFR atypical mutations at the ESMO Congress 2026, including confirmed systemic ORR of 84% and intracranial ORR of 70%, with multiple intracranial complete responses. The company plans to advance enozertinib into a global Phase 3 trial.

Company

About Oric Pharmaceuticals, Inc.

Oric Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapies that address resistance to treatment. The company’s research pipeline centers on precision oncology, hormone-dependent cancers, and key tumor dependencies, with current programs designed to target mechanisms that limit the effectiveness of existing cancer medicines. Its product candidates include therapies in clinical development for genetically defined cancers and prostate cancer, along with additional discovery-stage oncology programs. Oric Pharmaceuticals operates as a single business segment and concentrates its efforts on advancing research, clinical development, and translational science for cancer treatment. The company is headquartered in South San Francisco, California, with additional operations supporting its development work in the United States. Its role in the market is to contribute experimental oncology candidates to the broader pipeline of targeted cancer therapeutics.

CEO Dr. Jacob M. Chacko M.B.A., M.D. · 111 employees · United States · https://www.oricpharma.com